Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study

• Κύριοι συγγραφείς: Shinya Takasaki (Συγγραφέας), Hiroaki Yamaguchi (Συγγραφέας), Yoshihide Kawasaki (Συγγραφέας), Masafumi Kikuchi (Συγγραφέας), Masaki Tanaka (Συγγραφέας), Akihiro Ito (Συγγραφέας), Nariyasu Mano (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: BMC, 2019-03-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

Abstract Background Everolimus is an oral inhibitor of mammalian target of rapamycin, approved for metastatic renal cell carcinoma (mRCC). Recently, personalized medicine through therapeutic drug monitoring (TDM) is recommended in cancer therapy. In this study, the relationship between everolimus bl...